Semaglutide Distribution Flexibility: EMA Appro...

By João L. Carapinha

April 13, 2026

The European Medicines Agency (EMA) has granted an important update to the product information for Wegovy (semaglutide), introducing semaglutide distribution flexibility that allows controlled-temperature delivery at up to 30°C for up to 48 hours ...
Shift in Portuguese Pediatric Vaccination Policy: Evolving Perspectives on Ri...
Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch
Antimicrobial Resistance Art: Bridging Science and Health Through Visual Stor...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007
Impact of Insulin Copay Caps on Medicare Beneficiary Health and Spending
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role...
Advancements in Immunotherapy for Hepatocellular Carcinoma: EMERALD-3 Trial R...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Tre...
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strat...
Personalised Fertility Endometriosis Care in the UK
Tarlatamab for Small Cell Lung Cancer Treatment
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management